Skip to navigation Skip to content

Systemic light chain amyloidosis (AL) Program in Pharmaceutical Benefits Scheme (PBS) 012-22121931

Expand/Collapse all sectionsExpand all


This document outlines details of PBS-subsidised daratumumab for patients with systemic light chain amyloidosis.

For information on how to process a PBS Authority, see Processing new Authority requests in the Pharmaceutical Benefits Scheme (PBS), and Processing an existing Authority request in the Pharmaceutical Benefits Scheme (PBS).

Systemic light chain amyloidosis (AL) quick reference

Restrictions

Authority level and section

PA assessment

Processing system

Prescriber type

Prescriber self-serve

Initial

PB341 form

 

Written

Electronic

S85:

daratumumab

No

OPA

Must be treated by a:

  • haematologist

Yes

Continuing

Telephone

Electronic

S85:

daratumumab

No

OPA

Must be treated by a:

  • haematologist

Yes